| Autor: |
Tekin V; Institute of Nuclear Sciences, Ege University, Izmir, Turkey., Kozgus Guldu O; Institute of Nuclear Sciences, Ege University, Izmir, Turkey., Medine EI; Institute of Nuclear Sciences, Ege University, Izmir, Turkey., Biber Muftuler FZ; Institute of Nuclear Sciences, Ege University, Izmir, Turkey. |
| Jazyk: |
angličtina |
| Zdroj: |
Cancer biotherapy & radiopharmaceuticals [Cancer Biother Radiopharm] 2021 May; Vol. 36 (4), pp. 326-332. Date of Electronic Publication: 2020 May 21. |
| DOI: |
10.1089/cbr.2020.3602 |
| Abstrakt: |
Background: Prostate cancer is the most common type of cancer for men in many countries. One of the various prostate cancer therapy methods is hormone therapy, and explaining the association between androgen hormones and prostate cancer is a critical role for successful prostate cancer treatment. Materials and Methods: In the current study, the behavior of 3,4-divanillyltetrahydrofuran (DTH) was examined against prostate cancer cells, which have androgen sensitivity differences [LNCaP (+), PC3 (-)]. For this aim, DTH was obtained by extraction of Urtica dioica roots. The molecular structure of isolated compound was confirmed as DTH by liquid chromatography-mass spectrometry and nuclear magnetic resonance spectroscopy analyses. To evaluate the association of androgen sensitivity, DTH was radiolabeled with 131 I, and cell uptake assay was performed by using 131 I-radiolabeled DTH. Also, cytotoxicity (WST-1) assay of DTH was performed against LNCaP and PC3 cells to determinate the toxic effects of DTH on different androgen mechanisms. Results: The results of assays on cells have shown that DTH lignan behaves different like being more toxic to LNCaP cells than PC3 cells, depending on androgen sensitivity. Conclusion: The results may contribute both the research topics of phytolignan prostate cancer and androgen-sensitive prostate cancer. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
